<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font6" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font7" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font8" size="9" family="GillSans,BoldItalic" color="#000000"/>
<text top="41" left="55" width="162" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Genetic Vaccines and Therapy 2007, 5 :5<i>Genetic Vaccines and Therapy</i></text>
<text top="41" left="394" width="160" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.gvt-journal.com/content/5/1/5</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="107" segment_no="10" tag_type="text">Page 6 of 9<b>5</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="108" segment_no="11" tag_type="text">(page number not for citation purposes)</text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="text">ticipants [41]. Of these, three did not receive any cell infu-</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="text">sions. Patients received modified CD8 + cell infusions</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="4" segment_no="2" tag_type="text">either alone or with IL-2. The group receiving IL-2 with the<i>(page number not for citation purposes)</i></text>
<text top="121" left="55" width="241" height="10" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">modified CD8 + cells showed higher levels of persistence<a href="">41</a>]. Of these, three did not receive any cell infu-</text>
<text top="131" left="55" width="241" height="13" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">of CD4 ζ as compared to the group receiving no IL-2 sup-</text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">plementation. In order to test whether the IL2 was substi-</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="2" tag_type="text">tuting for HIV-specific CD4 + T-cell help, 17 of the 30</text>
<text top="168" left="55" width="241" height="10" font="font4" id="p1_t12" reading_order_no="9" segment_no="2" tag_type="text">participants received modified CD4 + cells along with</text>
<text top="180" left="55" width="242" height="10" font="font4" id="p1_t13" reading_order_no="10" segment_no="2" tag_type="text">modified CD8 + cells in a second series of infusions. Mod-</text>
<text top="192" left="55" width="242" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="2" tag_type="text">ified CD8 + and CD4 + cells were detected in the peripheral</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="2" tag_type="text">blood of these 17 patients for at least one year post-infu-</text>
<text top="215" left="55" width="241" height="10" font="font4" id="p1_t16" reading_order_no="13" segment_no="2" tag_type="text">sion, indicating that co-administration of the CD4 + cells</text>
<text top="227" left="55" width="241" height="10" font="font4" id="p1_t17" reading_order_no="14" segment_no="2" tag_type="text">may have increased survival of the modified CD8 + cells</text>
<text top="239" left="55" width="20" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="2" tag_type="text">[41].</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="5" tag_type="text">In the same year that Walker et al . reported their findings,</text>
<text top="275" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="5" tag_type="text">Mitsuyasu and fellow researchers published the results of</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="5" tag_type="text">a similar chimeric receptor study [42]. Patients enrolled in</text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="5" tag_type="text">this study were receiving anti-retroviral therapy (ART) and</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="5" tag_type="text">had viral loads between 1,000 and 100,000 copies/ml and</text>
<text top="321" left="55" width="241" height="10" font="font4" id="p1_t24" reading_order_no="21" segment_no="5" tag_type="text">CD4 + T cell counts greater than 50 per microliter. Follow-</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="5" tag_type="text">ing cell infusions, patients were followed for eight weeks.</text>
<text top="343" left="55" width="241" height="13" font="font4" id="p1_t26" reading_order_no="23" segment_no="5" tag_type="text">Eleven patients received CD4 ζ -modified T cells along with</text>
<text top="355" left="55" width="241" height="13" font="font4" id="p1_t27" reading_order_no="24" segment_no="5" tag_type="text">IL-2, and thirteen patients received CD4 ζ -modified T cells</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="5" tag_type="text">alone. In contrast to the previous study by Walker et al .,</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="5" tag_type="text">administration of IL-2 did not increase the survival of the</text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="5" tag_type="text">modified T cells. However, an increase in cell number was</text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="5" tag_type="text">observed at eight weeks post-infusion; an average increase</text>
<text top="415" left="55" width="241" height="10" font="font4" id="p1_t32" reading_order_no="29" segment_no="5" tag_type="text">of 73 CD4 + cells per microliter was observed in the group</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="5" tag_type="text">receiving IL-2 as compared to the group that did not</text>
<text top="437" left="55" width="241" height="13" font="font4" id="p1_t34" reading_order_no="31" segment_no="5" tag_type="text">receive IL-2. They detected CD4 ζ in 1 to 3% of the periph-</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="5" tag_type="text">eral blood mononuclear cells (PBMCs) at eight weeks and</text>
<text top="460" left="55" width="241" height="13" font="font4" id="p1_t36" reading_order_no="33" segment_no="5" tag_type="text">0.1% at one year post-infusion. CD4 ζ -modified T-cells</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="5" tag_type="text">were also isolated from bulk rectal tissue and/or lamina</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="5" tag_type="text">propria lymphocytes in five of five patients at 14 days and</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="5" tag_type="text">two of three patients at one year, showing good tissue dis-</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="5" tag_type="text">tribution. In addition, there was a transient decrease of</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="5" tag_type="text">greater than 0.5 log mean in rectal tissue-associated HIV<a href="">[41].</a></text>
<text top="533" left="55" width="123" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="5" tag_type="text">RNA for at least 14 days [42].</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="8" tag_type="text">Encouraged by data from this trial, the same group con-<i>et al</i></text>
<text top="566" left="55" width="241" height="13" font="font4" id="p1_t44" reading_order_no="41" segment_no="8" tag_type="text">ducted a phase II randomized trial of CD4 ζ gene-modi-</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="8" tag_type="text">fied versus unmodified T cells in adult male HIV-positive</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="8" tag_type="text">patients in 2002 [43]. All participants were on combina-<a href="">y [42]. Pat</a>ients enrolled in</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="8" tag_type="text">tion ART. In 37 patients, there were no measurable viral</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="8" tag_type="text">loads (&lt;50 copies per ml). In three patients, low levels</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="8" tag_type="text">were detected (53, 57 and 65 copies per ml). Only 40 of</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="8" tag_type="text">42 enrolled patients proceeded to receive the study treat-</text>
<text top="648" left="55" width="241" height="13" font="font4" id="p1_t51" reading_order_no="48" segment_no="8" tag_type="text">ment. The researchers found good expression of CD4 ζ for</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="8" tag_type="text">at least 24 weeks in all patients. However, no significant</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="8" tag_type="text">difference was found between patients receiving gene</text>
<text top="686" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="8" tag_type="text">therapy versus the control group when the six following</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="8" tag_type="text">parameters were analyzed: plasma viral load, HIV co-cul-</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="8" tag_type="text">ture on PBMCs, blood HIV DNA, rectal biopsy DNA, rec-</text>
<text top="721" left="55" width="204" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="8" tag_type="text">tal biopsy RNA, and blood CD4 + cell count [43].</text>
<text top="87" left="313" width="170" height="9" font="font8" id="p1_t58" reading_order_no="55" segment_no="3" tag_type="title">RNA-based approaches used in the clinic</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="4" tag_type="text">A clinical trial involving RNA decoys was conducted in a</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="4" tag_type="text">pediatric population using an RRE decoy to modify<i>et al</i></text>
<text top="121" left="313" width="241" height="10" font="font4" id="p1_t61" reading_order_no="58" segment_no="4" tag_type="text">CD34 + bone marrow cells. Kohn et al . (1999) showed that</text>
<text top="133" left="313" width="241" height="10" font="font4" id="p1_t62" reading_order_no="59" segment_no="4" tag_type="text">retroviral mediated CD34 + cell transduction had no signif-</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="4" tag_type="text">icant adverse effects and that leukocytes containing an</text>
<text top="157" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="4" tag_type="text">RRE decoy could be isolated from peripheral blood, even</text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="4" tag_type="text">one year post-infusion; however, the numbers of trans-</text>
<text top="181" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="4" tag_type="text">duced cells were extremely low [44]. Four HIV-positive</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="4" tag_type="text">patients, three teenagers, and one eight-year-old were</text>
<text top="204" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="4" tag_type="text">enrolled in this pilot study. Bone marrow cells positive for</text>
<text top="216" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="4" tag_type="text">CD34 were isolated from these patients and transduced</text>
<text top="228" left="313" width="241" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="4" tag_type="text">with Moloney murine leukemia (MoMuLV) vector virus</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="4" tag_type="text">carrying the RRE decoy sequences. No change in the HIV</text>
<text top="251" left="313" width="221" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="4" tag_type="text">viral load was observed among the participants [44].</text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="6" tag_type="text">In 2004, Amado et al . demonstrated long-term mainte-</text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="6" tag_type="text">nance of a therapeutic transgene in a phase I clinical trial</text>
<text top="298" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="6" tag_type="text">involving ribozymes [45]. They used MoMLV vector virus</text>
<text top="309" left="313" width="241" height="10" font="font4" id="p1_t76" reading_order_no="73" segment_no="6" tag_type="text">transduction of CD34 + HSCs for introduction of a</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="6" tag_type="text">ribozyme targeted to highly conserved regions in the HIV-</text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="6" tag_type="text">1 tat and vpr genes. Ten patients participated in the study</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="6" tag_type="text">and researchers could detect the vector in naïve T cells for</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="6" tag_type="text">up to three years, the last time-point evaluated. There was</text>
<text top="368" left="313" width="241" height="10" font="font4" id="p1_t81" reading_order_no="78" segment_no="6" tag_type="text">an average increase of 10 CD4 + T cells per microliter from<a href="">42]</a>.</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t82" reading_order_no="79" segment_no="6" tag_type="text">the beginning of the trial until the third year. In six</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="6" tag_type="text">patients, viral loads decreased by an average of 2.25 logs.</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="6" tag_type="text">Three patients had undetectable viral loads. One patient</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="6" tag_type="text">showed an increase of one log. The researchers found no</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="6" tag_type="text">correlation between the changes in viremia or CD4 + T cell</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="6" tag_type="text">counts with vector expression or detection in any cell type.<a href="">[43</a>]. All participants were on combina-</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="6" tag_type="text">However, during this trial, all patients were on ART, and</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="6" tag_type="text">the researchers attribute the changes in viral load as well</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t90" reading_order_no="87" segment_no="6" tag_type="text">as the cell numbers to individual viral susceptibility to</text>
<text top="486" left="313" width="40" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="6" tag_type="text">ART [45].</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="7" tag_type="text">More recently in 2005, Macpherson et al . published the</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t93" reading_order_no="90" segment_no="7" tag_type="text">results of a phase I clinical trial on ribozymes involving</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t94" reading_order_no="91" segment_no="7" tag_type="text">identical twins with discordant HIV status [46]. Again,</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t95" reading_order_no="92" segment_no="7" tag_type="text">one twin acted as the donor (HIV-negative) and the other</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="7" tag_type="text">was the recipient (HIV-positive) of genetically engineered</text>
<text top="568" left="313" width="242" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="7" tag_type="text">CD4 + T cells expressing a ribozyme. Specifically, the cells</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t98" reading_order_no="95" segment_no="7" tag_type="text">were transduced with an anti-HIV-1 tat ribozyme (RRz2)</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="7" tag_type="text">and a control LNL6 retroviral vector (for cell marking).</text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t100" reading_order_no="97" segment_no="7" tag_type="text">Patients were followed initially for 24 weeks and then at</text>
<text top="615" left="313" width="241" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="7" tag_type="text">regular intervals over a 4-year period. PBMCs containing</text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="7" tag_type="text">both RRz2 and LNL6 were detected consistently. How-<a href="">[43</a>].</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="7" tag_type="text">ever, the effect of this therapy on HIV-1 viral load or the<i><b>RNA-based approaches used in the clinic</b></i></text>
<text top="651" left="313" width="177" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="7" tag_type="text">CD4 count was not specifically addressed.</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t105" reading_order_no="102" segment_no="9" tag_type="text">Lastly, Morgan et al . (2005) published data from a clinical</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t106" reading_order_no="103" segment_no="9" tag_type="text">trial involving anti-sense RNA in conjunction with a trans-</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t107" reading_order_no="104" segment_no="9" tag_type="text">dominant negative protein [47]. This study employed 10</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t108" reading_order_no="105" segment_no="9" tag_type="text">pairs of twins. Like the earlier study involving twins with</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t109" reading_order_no="106" segment_no="9" tag_type="text">discordant HIV status, one twin served as the donor (HIV-<i>et al</i></text>
</page>
</pdf2xml>
